Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study

Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study

<b>Background</b>: Advances in the treatment of type 2 diabetes (T2D) in recent decades have been primarily focused on its broader understanding in the context of the possibility of preventing the development and progression of the disease and of cardiovascular (CV) complications. Nevert...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tomislav Kurevija, Ema Schönberger, Matea Matić Ličanin, Ines Bilić-Ćurčić, Ljiljana Trtica-Majnarić, Silvija Canecki-Varžić
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	type 2 diabetes cardiovascular risk SGLT2ins GLP-1 RAs family medicine
Online Access:	https://www.mdpi.com/2227-9059/13/6/1491
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Barriers in prescribing antidiabetic medications with cardiovascular benefits: practice, experience, and attitudes of GPs in Croatia
by: Tomislav Kurevija, et al.
Published: (2025-05-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications
by: Xiangling Duan, et al.
Published: (2025-04-01)

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01)

The relationship between antidiabetic and renal cancer: a systematic review
by: Shadman Newaz, et al.
Published: (2025-06-01)

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01)

Handling method for GPS outages based on PSO-LSTM and fading adaptive Kalman filtering
by: Xiaoming Li, et al.
Published: (2025-04-01)

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review
by: George I. Lambrou, et al.
Published: (2025-04-01)

Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin
by: Steffen Flindt Nielsen, et al.
Published: (2025-01-01)

DRESS syndrome with the use of dapagliflozin: A case report and review of literature
by: Rebecca Badawi, et al.
Published: (2025-07-01)

Post‐hoc analysis of the tofogliflozin post‐marketing surveillance study (J‐STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMI
by: Hiroyuki Uchinuma, et al.
Published: (2025-04-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice
by: Helen Goodluck, et al.
Published: (2025-04-01)

Perioperative Considerations of Novel Antidiabetic Agents in Heart Failure Patients Undergoing Cardiac Surgery
by: Ashley Wang, et al.
Published: (2025-03-01)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies
by: Gang Fan, et al.
Published: (2025-06-01)

Multicenter, open label, randomized controlled superiority trial for availability to reduce nocturnal urination frequency: The TOP‐STAR study
by: Hanako Nakajima, et al.
Published: (2024-12-01)

The Role of Antidiabetic Drugs in Bone Health: Assessing the Risk of Osteoporosis Subtypes and Fractures Using Mendelian Randomization
by: Deng G, et al.
Published: (2025-04-01)

Response to letter to the editor: Letter by Chen et al. regarding article, “Assessment of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and other antidiabetic agents in Alzheimer's disease: A population-based study”
by: Mar Garcia – Zamora, et al.
Published: (2025-05-01)

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion
by: Aida Lydia, et al.
Published: (2023-01-01)

Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
by: Yuliya Lytvyn, et al.
Published: (2025-04-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
by: Siobhan Wagner, et al.
Published: (2023-12-01)

EVALUAREA EFICACITĂȚII TERAPIEI CU INHIBITORI SGLT2 LA PACIENȚII CU INSUFICIENȚĂ CARDIACĂ CU FRACȚIE DE EJECȚIE PĂSTRATĂ
by: Tatiana Cotonet, et al.
Published: (2025-03-01)

Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
by: Amin Roshdy Soliman, et al.
Published: (2025-06-01)

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator
by: Celestino Sardu, et al.
Published: (2025-06-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes
by: A. O. Bohun
Published: (2024-04-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

Performance Enhancement of GPS/INS Integrated Navigation System Using Wavelet Based De-noising method
by: narjes davari, et al.
Published: (2016-11-01)

Investigating How Genomic Contexts Impact IS5 Transposition Within the <i>Escherichia coli</i> Genome
by: Jonathan Onstead, et al.
Published: (2024-12-01)